Please login to the form below
BPDCN
This page shows the latest BPDCN news and features for those working in and with pharma, biotech and healthcare.
Orphan drugs dominate FDA's record-breaking year
The last few days of the year also saw approvals for Stemline Therapeutics’ Elzonris (tagraxofusp) – the first drug to be licensed for rare cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) – and
Latest news
-
Cellectis floored by patient death in CAR-T trial
The 78-year-old man with blastic plasmacytoid dendritic cell neoplasm (BPDCN) started the treatment with Cellectis' UCART123 candidate at the MD Anderson Cancer Centre in the US in mid-August ... Shares in Cellectis went into a nosedive on news of the
-
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
UCART123 is a gene-edited CAR-T cell therapy that targets CD123 and will be tested in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Client Services Director- Flexible Working
-
Negotiable
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Events Executive
-
DOE
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Manager – Healthcare advertising
-
Salary TBC
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- Gracell reports impressive data with one-day CAR-T for leukaemia
- Lucid Group increases footprint in UK, Asia Pacific and Middle East with the acquisition of HealthCare21
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Gracell reports impressive data with one-day CAR-T for leukaemia
- Pharma industry consensus: fix data strategy before pushing artificial intelligence and machine learning applications
- Zenopa delivers Communiqué prizes to winners
- Detecting Alzheimer’s ahead of a cure
- When it’s OK to not be OK: Bedrock breaks down mental health stigma
- Roche wins FDA breakthrough for Gazyva in lupus nephritis
- Programmatic methodology and why you should be using it
PMHub
Anatomy Health
We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...
Latest intelligence
- Detecting Alzheimer’s ahead of a cure
- A focus on promising new research...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
- Can you survive without the blue dot?
- Or has the digital world has replaced our brain...
Quick links
Infographics
